Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients

References

• Nettis E, Ortoncelli M, Pellacani G, et al. A multicenter study on the prevalence of clinical patterns and clinical phenotypes in adult atopic dermatitis. J Investig Allergol Clin Immunol. 2020;30:448–450. doi:10.18176/jiaci.0519
   PubMed Web of Science ®Google Scholar
• Ständer S, Ropper AH. Atopic dermatitis. N Engl J Med.2021;384:1136–1143. doi:10.1056/NEJMra2023911
   PubMed Web of Science ®Google Scholar
• Girolomoni G, de Bruin-weller M, Aoki V, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis. 2021;12:204062232110029. doi:10.1177/20406223211002979
   Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–2348. doi:10.1056/NEJMoa1610020
   PubMed Web of Science ®Google Scholar
• Akinlade B, Guttman-Yassky E, de Bruin-weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181:459–473. doi:10.1111/bjd.17869
   PubMed Web of Science ®Google Scholar
• Schneeweiss MC, Kim SC, Wyss R, et al. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study. J Am Acad Dermatol. 2021;84:300–311. doi:10.1016/j.jaad.2020.09.084
   PubMed Web of Science ®Google Scholar
• Ivert LU, Wahlgren C-F, Ivert L, et al. Eye complications during dupilumab treatment for severe atopic dermatitis. Acta Derm Venereol. 2019;99:375–378. doi:10.2340/00015555-3121
   PubMed Web of Science ®Google Scholar
• Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging Phase 2b trial. Lancet Lond Engl. 2016;387:40–52. doi:10.1016/S0140-6736(15)00388-8
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2017;389:2287–2303. doi:10.1016/S0140-6736(17)31191-1
   PubMed Web of Science ®Google Scholar
• de Bruin-weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized Phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178:1083–1101. doi:10.1111/bjd.16156
   PubMed Web of Science ®Google Scholar
• Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatol. 2020;156:131–143. doi:10.1001/jamadermatol.2019.3617
   PubMed Web of Science ®Google Scholar
• Liberman P, Shifera AS, Berkenstock M. Dupilumab-associated conjunctivitis in patients with atopic dermatitis. Cornea. 2020;39:784–786. doi:10.1097/ICO.0000000000002262
   PubMed Web of Science ®Google Scholar
• Paulose SA, Sherman SW, Dagi Glass LR, Suh LH. Dupilumab-associated blepharoconjunctivitis. Am J Ophthalmol Case Rep. 2019;16:100550. doi:10.1016/j.ajoc.2019.100550
   PubMedGoogle Scholar
• Shen E, Xie K, Jwo K, et al. Dupilumab-induced follicular conjunctivitis. Ocul Immunol Inflamm. 2019;27:1339–1341. doi:10.1080/09273948.2018.1533567
   PubMed Web of Science ®Google Scholar
• Roca-Ginés J, Rahhal-Ortuño M, Torres-Navarro I, et al. Cyclosporine 0.1% (Ikervis®) treatment in steroid-dependent dupilumab-associated conjunctivitis. Arch Soc Espanola Oftalmol. 2019;94:396–399. doi:10.1016/j.oftal.2019.04.013
   PubMedGoogle Scholar
• Wollenberg A, Ariens L, Thurau S, et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6:1778–1780.e1. doi:10.1016/j.jaip.2018.01.034
   PubMed Web of Science ®Google Scholar
• Bohner A, Topham C, Strunck J, et al. Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up. Cornea. 2021;40:584–589. doi:10.1097/ICO.0000000000002461
   PubMed Web of Science ®Google Scholar
• Rial MJ, Barroso B, Rodríguez-Bermejo C, Sastre J. Letter regarding “Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2019;7:753. doi:10.1016/j.jaip.2018.10.055
   PubMed Web of Science ®Google Scholar
• Achten R, Bakker D, Ariens L, et al. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9:1389–1392.e2. doi:10.1016/j.jaip.2020.09.042
   PubMed Web of Science ®Google Scholar
• Popiela MZ, Barbara R, Turnbull AMJ, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye. 2021;35:3277–3284. doi:10.1038/s41433-020-01379-9
   PubMed Web of Science ®Google Scholar
• Nettis E, Bonzano L, Patella V, et al. Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol. 2020;30:201–204. doi:10.18176/jiaci.0481
   PubMed Web of Science ®Google Scholar
• Morelli P, Gaspari M, Gabriele C, et al. Proteomic analysis from skin swabs reveals a new set of proteins identifying skin impairment in atopic dermatitis. Exp Dermatol. 2021;30:811–819. doi:10.1111/exd.14276
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC. Tear dysfunction and the Cornea: LXVIII Edward Jackson memorial lecture. Am J Ophthalmol. 2011;152:900–909.e1. doi:10.1016/j.ajo.2011.08.023
   PubMed Web of Science ®Google Scholar
• Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154:1208–1211. doi:10.1001/jamadermatol.2018.2690
   PubMed Web of Science ®Google Scholar
• Zirwas MJ, Wulff K, Beckman K. Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report. JAAD Case Rep. 2019;5:34–36. doi:10.1016/j.jdcr.2018.10.016
   PubMedGoogle Scholar
• Aszodi N, Thurau S, Seegräber M, et al. Management of dupilumab-associated conjunctivitis in atopic dermatitis. JDDG. 2019;17:488–491.
   Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet Lond Engl. 2016;388:31–44. doi:10.1016/S0140-6736(16)30307-5
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475–2485. doi:10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a Randomized Clinical Trial. JAMA. 2016;315:469–479. doi:10.1001/jama.2015.19330
   PubMed Web of Science ®Google Scholar
• Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a Phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158:111–122.e10. doi:10.1053/j.gastro.2019.09.042
   PubMed Web of Science ®Google Scholar
• Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol. 2018;178:1220. doi:10.1111/bjd.16330
   PubMed Web of Science ®Google Scholar
• Thyssen JP, de Bruin-weller MS, Paller AS, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. JEADV. 2019;33:1224–1231. doi:10.1111/jdv.15608
   Web of Science ®Google Scholar
• Bakker DS, Ariens LFM, van Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180:1248–1249. doi:10.1111/bjd.17538
   PubMed Web of Science ®Google Scholar